SV2017005433A - Síntesis de copanlisib y su sal diclorhidrato - Google Patents
Síntesis de copanlisib y su sal diclorhidratoInfo
- Publication number
- SV2017005433A SV2017005433A SV2017005433A SV2017005433A SV2017005433A SV 2017005433 A SV2017005433 A SV 2017005433A SV 2017005433 A SV2017005433 A SV 2017005433A SV 2017005433 A SV2017005433 A SV 2017005433A SV 2017005433 A SV2017005433 A SV 2017005433A
- Authority
- SV
- El Salvador
- Prior art keywords
- copanlisib
- diclorhydrate
- synthesis
- salt
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE RELACIONA CON UN NUEVO MÉTODO PARA PREPARAR COPANLISIB, DICLORHIDRATO DE COPANLISIB, O HIDRATOS DE DICLORHIDRATO DE COPANLISIB, CON NUEVOS COMPUESTOS INTERMEDIARIOS, Y CON EL USO DE DICHOS NUEVOS COMPUESTOS INTERMEDIARIOS EN LA PREPARACIÓN DE COPANLISIB, DICLORHIDRATO DE COPANLISIB, O HIDRATOS DE DICLORHIDRATO DE COPANLISIB. LA PRESENTE INVENCIÓN TAMBIÉN SE RELACIONA CON HIDRATOS DE DICLORHIDRATO DE COPANLISIB COMO COMPUESTOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192203.9A EP3018127A1 (en) | 2014-11-07 | 2014-11-07 | Synthesis of copanlisib and its dihydrochloride salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005433A true SV2017005433A (es) | 2018-04-30 |
Family
ID=51866061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005433A SV2017005433A (es) | 2014-11-07 | 2017-05-05 | Síntesis de copanlisib y su sal diclorhidrato |
Country Status (47)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| JP2020533292A (ja) | 2017-09-08 | 2020-11-19 | バイエル・コンシューマー・ケア・アクチェンゲゼルシャフトＢａｙｅｒ Ｃｏｎｓｕｍｅｒ Ｃａｒｅ ＡＧ | コパンリシブの製剤 |
| WO2023139125A1 (en) | 2022-01-18 | 2023-07-27 | Synthon B.V. | Improved process for preparation of copanlisib |
| WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003580A (en) | 1910-08-10 | 1911-09-19 | Remington Typewriter Co | Type-writing machine. |
| US6221877B1 (en) * | 2000-04-12 | 2001-04-24 | Regents Of The University Of California | Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases |
| IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
| TW565582B (en) * | 2001-04-13 | 2003-12-11 | Kaneka Corp | Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them |
| EP1417204B1 (en) * | 2001-08-15 | 2006-01-18 | E. I. du Pont de Nemours and Company | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests |
| SI1549652T1 (sl) | 2002-09-30 | 2009-04-30 | Bayer Healthcare Ag | Kondenzirani azolpirimidinski derivati |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| US8859572B2 (en) | 2008-01-14 | 2014-10-14 | Bayer Intellectual Property Gmbh | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| JP6499657B2 (ja) | 2013-12-03 | 2019-04-10 | バイエル ファーマ アクチエンゲゼルシャフト | Ｐｉ３ｋ阻害剤の組み合わせ |
| EP3018131A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CA2978830A1 (en) | 2015-03-09 | 2016-09-15 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| EP3268005A1 (en) | 2015-03-09 | 2018-01-17 | Bayer Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| TN2018000271A1 (en) | 2016-02-01 | 2020-01-16 | Bayer Pharma AG | Copanlisib biomarkers. |
| JP2019512003A (ja) | 2016-02-01 | 2019-05-09 | バイエル ファーマ アクチエンゲゼルシャフト | コパンリシブバイオマーカー |
| EP3426657B1 (en) | 2016-03-08 | 2022-07-13 | Bayer Pharma Aktiengesellschaft | 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides |
| CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
-
2014
- 2014-11-07 EP EP14192203.9A patent/EP3018127A1/en not_active Withdrawn
-
2015
- 2015-11-04 JO JOP/2015/0274A patent/JO3644B1/ar active
- 2015-11-05 CR CR20170184A patent/CR20170184A/es unknown
- 2015-11-05 TR TR2019/05217T patent/TR201905217T4/tr unknown
- 2015-11-05 MX MX2017005893A patent/MX366904B/es active IP Right Grant
- 2015-11-05 UY UY0001036392A patent/UY36392A/es not_active Application Discontinuation
- 2015-11-05 MA MA40895A patent/MA40895B1/fr unknown
- 2015-11-05 MY MYPI2017701550A patent/MY189852A/en unknown
- 2015-11-05 PL PL15790150T patent/PL3215493T3/pl unknown
- 2015-11-05 UA UAA201705433A patent/UA122398C2/uk unknown
- 2015-11-05 AU AU2015341788A patent/AU2015341788B2/en active Active
- 2015-11-05 HU HUE15790150A patent/HUE042866T2/hu unknown
- 2015-11-05 DK DK15790150.5T patent/DK3215493T3/da active
- 2015-11-05 ES ES15790150T patent/ES2721778T3/es active Active
- 2015-11-05 EP EP15790150.5A patent/EP3215493B1/en active Active
- 2015-11-05 CU CU2017000061A patent/CU24489B1/es unknown
- 2015-11-05 RS RS20190453A patent/RS58579B1/sr unknown
- 2015-11-05 EA EA201790983A patent/EA035558B1/ru not_active IP Right Cessation
- 2015-11-05 KR KR1020177014992A patent/KR102566834B1/ko active IP Right Grant
- 2015-11-05 SG SG11201703702RA patent/SG11201703702RA/en unknown
- 2015-11-05 ME MEP-2019-107A patent/ME03358B/me unknown
- 2015-11-05 US US15/524,581 patent/US10494372B2/en active Active
- 2015-11-05 BR BR112017009470-3A patent/BR112017009470B1/pt active IP Right Grant
- 2015-11-05 SI SI201530695T patent/SI3215493T1/sl unknown
- 2015-11-05 CA CA2966800A patent/CA2966800C/en active Active
- 2015-11-05 CN CN201580072735.8A patent/CN107278204B/zh active Active
- 2015-11-05 JP JP2017523881A patent/JP6691115B2/ja active Active
- 2015-11-05 NZ NZ731287A patent/NZ731287A/en unknown
- 2015-11-05 TN TN2017000179A patent/TN2017000179A1/en unknown
- 2015-11-05 WO PCT/EP2015/075789 patent/WO2016071435A2/en active Application Filing
- 2015-11-05 PE PE2017000818A patent/PE20170897A1/es unknown
- 2015-11-05 PT PT15790150T patent/PT3215493T/pt unknown
- 2015-11-05 LT LTEP15790150.5T patent/LT3215493T/lt unknown
- 2015-11-06 AR ARP150103619A patent/AR102570A1/es unknown
- 2015-11-06 TW TW104136742A patent/TWI697495B/zh active
-
2017
- 2017-04-24 IL IL251874A patent/IL251874A0/en active IP Right Grant
- 2017-05-04 PH PH12017500833A patent/PH12017500833A1/en unknown
- 2017-05-04 SA SA517381462A patent/SA517381462B1/ar unknown
- 2017-05-05 DO DO2017000112A patent/DOP2017000112A/es unknown
- 2017-05-05 NI NI201700054A patent/NI201700054A/es unknown
- 2017-05-05 CL CL2017001131A patent/CL2017001131A1/es unknown
- 2017-05-05 EC ECIEPI201727755A patent/ECSP17027755A/es unknown
- 2017-05-05 CO CONC2017/0004532A patent/CO2017004532A2/es unknown
- 2017-05-05 SV SV2017005433A patent/SV2017005433A/es unknown
- 2017-06-06 ZA ZA2017/03867A patent/ZA201703867B/en unknown
-
2018
- 2018-04-19 HK HK18105077.5A patent/HK1245774A1/zh unknown
-
2019
- 2019-04-16 HR HRP20190720TT patent/HRP20190720T1/hr unknown
- 2019-04-23 CY CY20191100444T patent/CY1121602T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005433A (es) | Síntesis de copanlisib y su sal diclorhidrato | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| CL2017001130A1 (es) | Síntesis de copanlisib y su sal diclorhidrato | |
| CL2016002055A1 (es) | Uso de compuestos 3-isoxazolidinonas como herbicidas selectivos | |
| BR112016025427A2 (pt) | processos de preparação de um inibidor de jak1 e formas do mesmo | |
| ECSP16061758A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CR20160098A (es) | Polimorfo de los inhibidores de la syk | |
| NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| TWD171885S (zh) | 汽車用水箱護罩桿 | |
| EA202092609A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| BR112017013767A2 (pt) | uso de picolinamidas como fungicidas | |
| ES2897914T8 (es) | Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos | |
| EA201691367A1 (ru) | Кристаллические формы дималеата афатиниба | |
| BR112016017402A2 (pt) | fusões anti-pcsk9~glp-1 e métodos para uso | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| BR112016022691A2 (pt) | uso de compostos heterocíclicos para controlar nematódeos. | |
| MX2016014765A (es) | Incremento del rendimiento utilizando soforolipidos. | |
| BR112016029510A2 (pt) | métodos para a preparação de um composto, e, composto intermediário. | |
| CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
| BR112017001391A2 (pt) | componentes para o fusionamento de corpos vertebrais | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| BR112017008854A2 (pt) | partículas de cadotrila | |
| EA201690263A1 (ru) | Улучшенные способы получения перампанеля | |
| UY36434A (es) | Nuevas formas cristalinas de la sal de monosodio del foramsulfurón |